Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) Operating Margin: 2018-2025

Historic Operating Margin for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to 22,971.82%.

  • Cidara Therapeutics' Operating Margin rose 2384972.00% to 22,971.82% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,572.19%, marking a year-over-year decrease of 145441.00%. This contributed to the annual value of -13,811.92% for FY2024, which is 1369570.00% down from last year.
  • Cidara Therapeutics' Operating Margin amounted to 22,971.82% in Q1 2025, which was up 172.28% from -31,782.78% recorded in Q2 2024.
  • Cidara Therapeutics' 5-year Operating Margin high stood at 22,971.82% for Q1 2025, and its period low was -31,782.78% during Q2 2024.
  • Over the past 3 years, Cidara Therapeutics' median Operating Margin value was -78.39% (recorded in 2023), while the average stood at -1,421.39%.
  • Its Operating Margin has fluctuated over the past 5 years, first plummeted by 3,165,021bps in 2024, then surged by 2,384,972bps in 2025.
  • Over the past 5 years, Cidara Therapeutics' Operating Margin (Quarterly) stood at -598.93% in 2021, then skyrocketed by 46,695bps to -131.98% in 2022, then spiked by 5,359bps to -78.39% in 2023, then slumped by 3,165,021bps to -31,782.78% in 2024, then soared by 2,384,972bps to 22,971.82% in 2025.
  • Its last three reported values are 22,971.82% in Q1 2025, -31,782.78% for Q2 2024, and -877.90% during Q1 2024.